Bench to bedside: episode 4 - "from biomarker to surrogate"
BIA’s Science and Innovation Advisory Committee (SIAC) are delivering a series of webinars in 2019 titled ‘Bench to Bedside’. The content has been proposed by industry and will explore the drug discovery process from discovery to delivery. The series will be concluded with a panel session at our UK Bioscience Forum on 17 October.
This session will discuss the types of biomarker used in preclinical and clinical development and considers the factors leading to biomarker qualification as well as steps which may lead to approval of the marker as a surrogate endpoint for drug approval.
Dr Penny Ward
Dr Penny Ward qualified in medicine from the University College Hospital, London. After a career in academic medicine and specialization in OBGYN, Penny entered the pharmaceutical industry in 1991. During her extensive industry career, she has held positions of increasing seniority in several companies including Pharmacia & Upjohn, GlaxoSmithKline, F Hoffman- La Roche and UCB and has served as Chief Medical Officer at Novimmune, Glenmark, Topivert, Karus Therapeutics and Blue Earth Diagnostics. Her work has contributed to the successful licensing and launch of multiple novel treatments and diagnostics in the fields of infectious disease, osteoporosis, autoimmune disorders and cancer in the EU, US and Japan. She is a Fellow of the Faculty of Pharmaceutical Medicine and Visiting Senior Lecturer at Kings College, London.
Next episodes 2019:
Concluding session - UK Bioscience Forum, 17 October, London
Thank you Clinical Professionals